

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

09/974,654

Filing Date

09-OCT-01

First Named Inventor

Alsobrook et al.

Art Unit

1646

Examiner Name

Michael T. Brannock

Attorney Docket Number

Cura 154 CIP

**ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a  
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):Return Postcard, Grant of Associate Power  
of Attorney

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

CuraGen Corporation

Signature

Printed name

Daniel K. Rieger

Date

April 6, 2005

Reg. No.

56,436

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name


Lissette Cartagena Perez

Date

April 6, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Date of Deposit: April 6, 2005

Attorney Docket No. Cura 154 CIP

1646  
Jh

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Alsobrook, et al  
SERIAL NUMBER: 09/974,591 EXAMINER: Michael T. Brannock  
FILING DATE: October 09, 2001 ART UNIT: 1646  
FOR: NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS FOR OLFACTORY  
RECEPTOR-LIKE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING  
THE SAME

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT UNDER 37 C.F.R. § 1.111**

Sir:

This paper is in response to the Office Action mailed December 6, 2004, in the above-referenced application. In accordance with the Rules of Practice, please enter the following amendments and consider the remarks below.

A petition for a one-month extension of time was filed on March 31, 2006. With a one-month extension of time, a response is due on April 6, 2005 and is hereby filed. The Commissioner is hereby authorized to charge any additional fees that may be due to Deposit Account No. 502648, Reference No. Cura 154 CIP. Applicants request small entity status.

**Amendments to the Specification** are shown on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 3 of this paper.

**Remarks** begin on page 5 of this paper.